Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3

被引:58
|
作者
Van Maerken, Tom [1 ,2 ]
Rihani, Ali [1 ]
Dreidax, Daniel [4 ]
De Clercq, Sarah [3 ]
Yigit, Nurten [1 ]
Marine, Jean-Christophe [3 ]
Westermann, Frank [4 ]
De Paepe, Anne [1 ]
Vandesompele, Jo [1 ]
Speleman, Frank [1 ]
机构
[1] Ghent Univ Hosp, Ctr Genet Med, B-9000 Ghent, Belgium
[2] Ghent Univ Hosp, Dept Clin Chem Microbiol & Immunol, B-9000 Ghent, Belgium
[3] VIB UGent, Lab Mol Canc Biol, Ghent, Belgium
[4] German Canc Res Ctr, Dept Tumor Genet, D-6900 Heidelberg, Germany
关键词
WILD-TYPE P53; ARF TUMOR-SUPPRESSOR; P53/MDM2/P14(ARF) PATHWAY; CYTOPLASMIC SEQUESTRATION; SENSITIZES NEUROBLASTOMA; INDUCED APOPTOSIS; GENE-MUTATIONS; LINES; FREQUENCY; NUCLEAR;
D O I
10.1158/1535-7163.MCT-10-1090
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Suppression of p53 activity is essential for proliferation and survival of tumor cells. A direct p53-activating compound, nutlin-3, was used in this study, together with p53 mutation analysis, to characterize p53 pathway defects in a set of 34 human neuroblastoma cell lines. We identified 9 cell lines (26%) with a p53 loss-of-function mutation, including 6 missense mutations, 1 nonsense mutation, 1 in-frame deletion, and 1 homozygous deletion of the 30 end of the p53 gene. Sensitivity to nutlin-3 was highly predictive of absence of p53 mutation. Signaling pathways downstream of p53 were functionally intact in 23 of 25 cell lines with wild-type p53. Knockdown and overexpression experiments revealed a potentiating effect of p14(ARF) expression on the response of neuroblastoma cells to nutlin-3. Our findings shed light on the spectrum of p53 pathway lesions in neuroblastoma cells, indicate that defects in effector molecules downstream of p53 are remarkably rare in neuroblastoma, and identify p14(ARF) as a determinant of the outcome of the response to MDM2 inhibition. These insights may prove useful for the clinical translation of evolving strategies aimed at p53 reactivation and for the development of new therapeutic approaches. Mol Cancer Ther; 10(6); 983-93. (C)2011 AACR.
引用
收藏
页码:983 / 993
页数:11
相关论文
共 50 条
  • [1] Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3
    Huang, Baoying
    Vassilev, Lyubomir T.
    [J]. AGING-US, 2009, 1 (10): : 845 - 854
  • [2] p53 mutations induced by the MDM2 inhibitor nutlin-3 in p53 wild-type neuroblastoma cells
    Michaelis, M.
    Wass, M.
    Cinatl, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 69 : S72 - S72
  • [3] Mdm2 antagonist Nutlin-3 induces apoptosis in p53 mutant human colon carcinoma cells
    Bhattacharya, Sujoy
    Ray, Ramesh M.
    Johnson, Leonard R.
    [J]. FASEB JOURNAL, 2009, 23
  • [4] Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
    A K Arya
    A El-Fert
    T Devling
    R M Eccles
    M A Aslam
    C P Rubbi
    N Vlatković
    J Fenwick
    B H Lloyd
    D R Sibson
    T M Jones
    M T Boyd
    [J]. British Journal of Cancer, 2010, 103 : 186 - 195
  • [5] Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
    Arya, A. K.
    El-Fert, A.
    Devling, T.
    Eccles, R. M.
    Aslam, M. A.
    Rubbi, C. P.
    Vlatkovic, N.
    Fenwick, J.
    Lloyd, B. H.
    Sibson, D. R.
    Jones, T. M.
    Boyd, M. T.
    [J]. BRITISH JOURNAL OF CANCER, 2010, 103 (02) : 186 - 195
  • [6] Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53
    Van Maerken, Tom
    Ferdinande, Liesbeth
    Taildeman, Jasmien
    Lambertz, Irina
    Yigit, Nurten
    Vercruysse, Liesbeth
    Rihani, Ali
    Michaelis, Martin
    Cinatl, Jindrich, Jr.
    Cuvelier, Claude A.
    Marine, Jean-Christophe
    De Paepe, Anne
    Bracke, Marc
    Speleman, Frank
    Vandesompele, Jo
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (22) : 1562 - 1574
  • [7] The MDM2 antagonist nutlin-3 is lethal to mantle cell lymphoma with wild type p53
    Tabe, Yoko
    Szbasigari, Denise
    Rudelius, Martina
    Pittaluga, Stefania
    Raffel, Mark
    [J]. BLOOD, 2007, 110 (11) : 415A - 415A
  • [8] In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
    Vassilev, LT
    Vu, BT
    Graves, B
    Carvajal, D
    Podlaski, F
    Filipovic, Z
    Kong, N
    Kammlott, U
    Lukacs, C
    Klein, C
    Fotouhi, N
    Liu, EA
    [J]. SCIENCE, 2004, 303 (5659) : 844 - 848
  • [9] Analysis of the MDM2 antagonist nutlin-3 in human prostate cancer cells
    Logan, Ian R.
    McNeill, Hesta V.
    Cook, Susan
    Lu, Xiaohong
    Lunec, John
    Robson, Craig N.
    [J]. PROSTATE, 2007, 67 (08): : 900 - 906
  • [10] How Nutlin-3 disrupts the MDM2–p53 interaction: a theoretical investigation
    Shah Md. Abdur Rauf
    Hiromitsu Takaba
    Carlos A. Del Carpio
    Akira Miyamoto
    [J]. Medicinal Chemistry Research, 2014, 23 : 1998 - 2006